Eli Lilly Invests $5.3B to Expand Indiana Plant for Weight-Loss Drugs
TL;DR Summary
Eli Lilly is investing an additional $5.3 billion in its Indiana manufacturing plant to increase the supply of its popular weight loss drug Zepbound and diabetes treatment Mounjaro, bringing the total investment at the site to $9 billion. The plant, expected to start operations by the end of 2026, will help address the high demand and shortages of these drugs. This marks Eli Lilly's largest manufacturing investment in its history.
- Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply CNBC
- Lilly increases investment to Lebanon manufacturing site to $9B WTHR
- Eli Lilly to Spend $5.3 Billion to Boost Output of Mounjaro and Zepbound The Wall Street Journal
- Eli Lilly commits $5.3B to up weight-loss drug production Yahoo Finance
- Eli Lilly adds $5.3 billion investment in Lebanon LEAP district FOX 59 Indianapolis
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
82%
386 → 70 words
Want the full story? Read the original article
Read on CNBC